Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923480 · ClinicalTrials.gov registry record · Phase 4
Dosing Study of Amino Acids in Seriously Ill Patients
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01923480 is a Phase 4 study that was terminated before completion, run by Baxter Healthcare Corporation. The registered enrollment target is 16 participants.
The verdict
NCT01923480, a Phase 4 study, was terminated before completion, sponsored by Baxter Healthcare Corporation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the best rate of infusion of amino acids (15% CLINISOL - sulfite-free (Amino Acid) Injection) for nutrition in subjects with with stages II to IVB head and neck cancer.
Interventions
- DRUG 15% CLINISOL - Sulfite-free (Amino Acid) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01923480
The ClinicalTrials.gov registry entry for NCT01923480 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 15% CLINISOL - Sulfite-free (Amino Acid) Injection is the first listed.
NCT01923480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01923480 about?
NCT01923480 is a clinical study titled "Dosing Study of Amino Acids in Seriously Ill Patients". The purpose of this study is to determine the best rate of infusion of amino acids (15% CLINISOL - sulfite-free (Amino Acid) Injection) for nutrition in subjects with with stages II to IVB head and neck cancer.
What is the current status of trial NCT01923480?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2013-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01923480?
The interventions under investigation include: 15% CLINISOL - Sulfite-free (Amino Acid) Injection (DRUG).
Who is sponsoring clinical trial NCT01923480?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.